TriangleERAS-801 (NCT07089641)
ERAS-801 trial for EGFR-Altered IDH-Wildtype Glioblastoma or Gliosarcoma (NCT07089641). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with IDH wildtype glioblastoma or gliosarcoma whose tumor has an EGFR amplification or mutation.
The idea: test ERAS-801, an EGFR inhibitor taken by mouth. Some patients take it before and after surgery, others after recurrence, and some older newly diagnosed patients after surgery.
This phase 1 study plans 50 patients and tests safety and side effects. At UCLA's Jonsson Comprehensive Cancer Center in Los Angeles, Phioanh Nghiemphu leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.